Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Modulation of the tumour microenvironment in hepatocellular carcinoma by tyrosine kinase inhibitors: from modulation to combination therapy targeting the microenvironment
Authors
Keywords
-
Journal
Cancer Cell International
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-02-11
DOI
10.1186/s12935-021-02435-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib inhibits migration, invasion, and vasculogenic mimicry of hepatocellular carcinoma via targeting ID1‐mediated EMT
- (2021) Nan Zhang et al. MOLECULAR CARCINOGENESIS
- IL‑6 plays a crucial role in epithelial‑mesenchymal transition and pro‑metastasis induced by sorafenib in liver cancer
- (2021) Ke‑Wei Zhang et al. ONCOLOGY REPORTS
- Stabilization of snail maintains the sorafenib resistance of hepatocellular carcinoma cells
- (2021) Huan Zhao et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting Innate Immunity in Cancer Therapy
- (2021) Srikrishnan Rameshbabu et al. Vaccines
- Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
- (2021) Xiang-Yuan Luo et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Regorafenib enhances antitumor immunity via inhibition of p38 kinase/Creb1/Klf4 axis in tumor-associated macrophages
- (2021) Da-Liang Ou et al. Journal for ImmunoTherapy of Cancer
- Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment
- (2021) Ritu Shrestha et al. Journal of Clinical Medicine
- Modulation of the tumor microenvironment (TME) by melatonin
- (2021) Qi Mu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Immunomodulatory effects of lenvatinib plus anti‐PD1 in mice and rationale for patient enrichment in hepatocellular carcinoma
- (2021) Laura Torrens et al. HEPATOLOGY
- Macrophage Polarization States in the Tumor Microenvironment
- (2021) Ava J. Boutilier et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
- (2021) Jie Zhu et al. Cancer Medicine
- MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
- (2021) Akihiro Hirao et al. Cancers
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2020) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma
- (2020) Haijing Deng et al. Liver Cancer
- The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
- (2020) Shunjie Xia et al. EBioMedicine
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer
- (2020) Yolla Haibe et al. Frontiers in Oncology
- Role of Cellular, Molecular, and Tumor Microenvironment in Hepatocellular Carcinoma: Possible Targets and Future Directions in the Regorafenib Era
- (2020) Sarun Juengpanich et al. INTERNATIONAL JOURNAL OF CANCER
- Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
- (2020) Rongdang Fu et al. MEDICAL ONCOLOGY
- The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma
- (2020) Cheng-Chan Yu et al. MOLECULES
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect
- (2020) Huining Tian et al. Cancer Management and Research
- Nanoparticle Delivery of MnO2 and Antiangiogenic Therapy to Overcome Hypoxia-Driven Tumor Escape and Suppress Hepatocellular Carcinoma
- (2020) Chih-Chun Chang et al. ACS Applied Materials & Interfaces
- Current treatment options for HCC: from pharmacokinetics to efficacy and adverse events in liver cirrhosis.
- (2020) Giovanni Galati et al. CURRENT DRUG METABOLISM
- Valproic acid overcomes sorafenib resistance by reducing the migration of Jagged2-mediated Notch1 signaling pathway in hepatocellular carcinoma cells
- (2020) Jing Liu et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells
- (2020) Michela Anna Polidoro et al. WORLD JOURNAL OF GASTROENTEROLOGY
- IL-6/STAT3 Signaling Contributes to Sorafenib Resistance in Hepatocellular Carcinoma Through Targeting Cancer Stem Cells
- (2020) Yu Li et al. OncoTargets and Therapy
- The Intimate Relationship among EMT, MET and TME: A T(ransdifferentiation) E(nhancing) M(ix) to Be Exploited for Therapeutic Purposes
- (2020) Ralf Hass et al. Cancers
- Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
- (2019) Yoon Yang et al. SEMINARS IN LIVER DISEASE
- Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway
- (2019) Yu Kato et al. PLoS One
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib Induces Pyroptosis in Macrophages and Triggers Natural Killer Cell–Mediated Cytotoxicity Against Hepatocellular Carcinoma
- (2019) Carina Hage et al. HEPATOLOGY
- Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications
- (2019) Elisabetta Cariani et al. LIVER INTERNATIONAL
- Targeted therapy for hepatocellular carcinoma: Challenges and opportunities
- (2019) Shuzhen Chen et al. CANCER LETTERS
- From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
- (2019) Yaojie Fu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- 747PA phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
- (2019) J Llovet et al. ANNALS OF ONCOLOGY
- Sorafenib attenuated the function of natural killer cells infiltrated in HCC through inhibiting ERK1/2
- (2019) Chunxiao Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
- (2019) María José López-Grueso et al. Antioxidants
- Molecular insight of regorafenib treatment for colorectal cancer
- (2019) Hiroyuki Arai et al. CANCER TREATMENT REVIEWS
- Current discovery strategies for hepatocellular carcinoma therapeutics
- (2019) Qiuzi Dai et al. Expert Opinion on Drug Discovery
- Sorafenib suppresses TGF-β responses by inducing caveolae/lipid raft-mediated internalization/degradation of cell-surface type II TGF-β receptors: Implications in development of effective adjunctive therapy for hepatocellular carcinoma
- (2018) Chih-Ling Chung et al. BIOCHEMICAL PHARMACOLOGY
- Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells
- (2018) Jun Arai et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma
- (2018) Qing-guo Xu et al. Molecular Oncology
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
- (2018) Kabir A. Khan et al. Nature Reviews Clinical Oncology
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity
- (2018) Lucas Ferrari de Andrade et al. SCIENCE
- Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells
- (2018) Yingshi Zhang et al. Cell Death & Disease
- Blocking CDK1/PDK1/β-Catenin signaling by CDK1 inhibitor RO3306 increased the efficacy of sorafenib treatment by targeting cancer stem cells in a preclinical model of hepatocellular carcinoma
- (2018) Chuan Xing Wu et al. Theranostics
- Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
- (2018) Yun-Chieh Sung et al. Theranostics
- The hypoxic tumour microenvironment
- (2018) Varvara Petrova et al. Oncogenesis
- Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells
- (2018) Yong Sang Lee et al. NEOPLASIA
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
- (2018) Takayuki Kimura et al. CANCER SCIENCE
- Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
- (2018) Yu-Yang Lin et al. SEMINARS IN LIVER DISEASE
- Synergistic antitumor effect of a γ-secretase inhibitor PF-03084014 and sorafenib in hepatocellular carcinoma
- (2018) Xuran Yang et al. Oncotarget
- Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma
- (2018) Weibo Chen et al. FEBS Open Bio
- TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
- (2018) Wenliang Tan et al. EBioMedicine
- Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway
- (2018) Jichuang Wang et al. CANCER LETTERS
- Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging
- (2017) Seunghyun Lee et al. EUROPEAN RADIOLOGY
- Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo
- (2017) Melek M.E. Sunay et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells
- (2017) Jianhua Liu et al. International Journal of Medical Sciences
- A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
- (2017) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Me too-drugs with limited benefits — the tale of regorafenib for HCC
- (2017) Bishal Gyawali et al. Nature Reviews Clinical Oncology
- Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials
- (2017) Masatoshi Kudo ONCOLOGY
- Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib
- (2017) Dongxu Kang et al. YONSEI MEDICAL JOURNAL
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity
- (2017) Akash Patnaik et al. Cancer Discovery
- A Multikinase and DNA-PK Inhibitor Combination Immunomodulates Melanomas, Suppresses Tumor Progression, and Enhances Immunotherapies
- (2017) Alexander K. Tsai et al. Cancer Immunology Research
- Cost-effectiveness analysis of potentially curative and combination treatments for hepatocellular carcinoma with person-level data in a Canadian setting
- (2017) Hla-Hla Thein et al. Cancer Medicine
- C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells
- (2016) Shanshan Jiang et al. APPLIED MICROBIOLOGY AND BIOTECHNOLOGY
- Diverse macrophages polarization in tumor microenvironment
- (2016) Inmoo Rhee ARCHIVES OF PHARMACAL RESEARCH
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and point-mutant β-catenin
- (2016) Junyan Tao et al. HEPATOLOGY
- The impact of hypoxia on tumor-associated macrophages
- (2016) Anne-Theres Henze et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
- (2016) Kenji Ikeda et al. JOURNAL OF GASTROENTEROLOGY
- Targeting Androgen Receptor (AR)->IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression
- (2016) L. Shi et al. MOLECULAR CANCER THERAPEUTICS
- Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer
- (2016) Bowen Du et al. MOLECULES
- Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication
- (2016) Naoshi Nishida et al. ONCOLOGY
- Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance)
- (2016) Joleen M. Hubbard et al. Targeted Oncology
- Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer
- (2016) Li-Ching Fan et al. Oncotarget
- Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice
- (2016) Junjie Hu et al. Scientific Reports
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion
- (2015) Martin Franz Sprinzl et al. JOURNAL OF HEPATOLOGY
- Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer
- (2015) Vincenzo Bronte et al. NATURE MEDICINE
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma
- (2015) Xufu Wei et al. Oncotarget
- Sorafenib Inhibition of Hepatic Stellate Cell Proliferation in Tumor Microenvironment of Hepatocellular Carcinoma: A Study of the Sorafenib Mechanisms
- (2014) Zhi-min Geng et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
- (2014) W.-T. Tai et al. CLINICAL CANCER RESEARCH
- Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
- (2014) Anna R Kwilas et al. Journal of Translational Medicine
- Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma
- (2014) HAIYONG WANG et al. ONCOLOGY REPORTS
- Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists
- (2014) Jean-Baptiste Rey et al. Targeted Oncology
- Downregulation of signal transducer and activator of transcription 3 by sorafenib: A novel mechanism for hepatocellular carcinoma therapy
- (2014) Man-Hsin Hung WORLD JOURNAL OF GASTROENTEROLOGY
- Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales
- (2013) Asmaa E El-Kenawi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
- (2013) Virginia Hernandez–Gea et al. GASTROENTEROLOGY
- Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells
- (2013) Martin Franz Sprinzl et al. HEPATOLOGY
- Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice
- (2013) Yunching Chen et al. HEPATOLOGY
- Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: Heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17
- (2013) Guranda Chitadze et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity
- (2013) Mei-Ling Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors
- (2013) Franziska Stehle et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma
- (2013) Qiang-Bo Zhang et al. PLoS One
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Sorafenib Inhibits Hypoxia-Inducible Factor-1 Synthesis: Implications for Antiangiogenic Activity in Hepatocellular Carcinoma
- (2012) L.-p. Liu et al. CLINICAL CANCER RESEARCH
- Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: Growth inhibition, quiescence, and recovery
- (2012) Brian I. Carr et al. JOURNAL OF CELLULAR PHYSIOLOGY
- CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation
- (2011) Terence Kin Wah Lee et al. Cell Stem Cell
- Sorafenib inhibits transforming growth factor β1-Mediated Epithelial-Mesenchymal Transition and apoptosis in mouse hepatocytes
- (2011) Yue-Lei Chen et al. HEPATOLOGY
- Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model
- (2011) Mengde Cao et al. LABORATORY INVESTIGATION
- Sorafenib Inhibits the Hepatocyte Growth Factor-Mediated Epithelial Mesenchymal Transition in Hepatocellular Carcinoma
- (2011) T. Nagai et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3
- (2011) Fang-Ming Gu WORLD JOURNAL OF GASTROENTEROLOGY
- Cutting Edge: The Membrane Type Matrix Metalloproteinase MMP14 Mediates Constitutive Shedding of MHC Class I Chain-Related Molecule A Independent of A Disintegrin and Metalloproteinases
- (2010) G. Liu et al. JOURNAL OF IMMUNOLOGY
- The tumor microenvironment in hepatocellular carcinoma: Current status and therapeutic targets
- (2010) Ju Dong Yang et al. SEMINARS IN CANCER BIOLOGY
- Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9
- (2009) Keisuke Kohga et al. HEPATOLOGY
- Overexpression of eukaryotic initiation factor 5A2 enhances cell motility and promotes tumor metastasis in hepatocellular carcinoma
- (2009) Dong-Jiang Tang et al. HEPATOLOGY
- The Kinase Inhibitors Sunitinib and Sorafenib Differentially Affect NK Cell Antitumor Reactivity In Vitro
- (2009) M. Krusch et al. JOURNAL OF IMMUNOLOGY
- Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma
- (2009) R. C. Kane et al. ONCOLOGIST
- Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase
- (2008) J. Matsui et al. CLINICAL CANCER RESEARCH
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
- (2008) Scott L. Friedman PHYSIOLOGICAL REVIEWS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now